Currently, a number of additional clinical trials with substantial sample sizes are ongoing and promise to reveal if NET specific inhibition is therapeutic in schizophrenia, especially for cognitive symptoms such as poor concentration and memory (clinicaltrials.gov). The gene discussed is SLC6A2; the disease is schizophrenia.